IL179376D0 - Compounds and compositions as ppar modulators - Google Patents

Compounds and compositions as ppar modulators

Info

Publication number
IL179376D0
IL179376D0 IL179376A IL17937606A IL179376D0 IL 179376 D0 IL179376 D0 IL 179376D0 IL 179376 A IL179376 A IL 179376A IL 17937606 A IL17937606 A IL 17937606A IL 179376 D0 IL179376 D0 IL 179376D0
Authority
IL
Israel
Prior art keywords
compositions
compounds
ppar modulators
ppar
modulators
Prior art date
Application number
IL179376A
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US57413704P priority Critical
Priority to US64898505P priority
Priority to PCT/US2005/018167 priority patent/WO2005116000A1/en
Application filed by Irm Llc filed Critical Irm Llc
Publication of IL179376D0 publication Critical patent/IL179376D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/16Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
IL179376A 2004-05-24 2006-11-16 Compounds and compositions as ppar modulators IL179376D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US57413704P true 2004-05-24 2004-05-24
US64898505P true 2005-01-31 2005-01-31
PCT/US2005/018167 WO2005116000A1 (en) 2004-05-24 2005-05-24 Compounds and compositions as ppar modulators

Publications (1)

Publication Number Publication Date
IL179376D0 true IL179376D0 (en) 2007-03-08

Family

ID=35450818

Family Applications (1)

Application Number Title Priority Date Filing Date
IL179376A IL179376D0 (en) 2004-05-24 2006-11-16 Compounds and compositions as ppar modulators

Country Status (16)

Country Link
US (1) US20070203155A1 (en)
EP (1) EP1748993A4 (en)
JP (1) JP2008500355A (en)
AR (1) AR049284A1 (en)
AU (1) AU2005247931B2 (en)
BR (1) BRPI0511477A (en)
CA (1) CA2563818A1 (en)
EC (1) ECSP067021A (en)
IL (1) IL179376D0 (en)
MA (1) MA28660B1 (en)
MX (1) MXPA06013591A (en)
NO (1) NO20065984L (en)
PE (1) PE20060315A1 (en)
RU (1) RU2413723C2 (en)
TW (1) TW200612926A (en)
WO (1) WO2005116000A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
US20070015839A1 (en) * 2005-07-14 2007-01-18 Franco Folli Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome
PE20070180A1 (en) 2005-07-26 2007-04-25 Glaxo Group Ltd Benzylpiperazine compounds as agonists of the GPR38
DE102005035891A1 (en) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals
CA2626483A1 (en) * 2005-11-07 2007-05-18 Irm Llc Compounds and compositions as ppar modulators
JP2009514974A (en) * 2005-11-07 2009-04-09 アイアールエム・リミテッド・ライアビリティ・カンパニーIrm,Llc Compounds and compositions as PPAR modulators
TW200732331A (en) * 2005-12-28 2007-09-01 Takeda Pharmaceuticals Co Fused heterocyclic compound and use thereof
PE20110235A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int pharmaceutical combinations comprising metformin and linagliptin
CA2810839A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
WO2008083124A1 (en) 2006-12-28 2008-07-10 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
AU2008218951B2 (en) * 2007-02-22 2011-11-17 Irm Llc Compounds and methods for modulating g protein-coupled receptors
NZ585298A (en) 2007-11-16 2012-08-31 Rigel Pharmaceuticals Inc Carboxamide, sulfonamide and amine compounds for metabolic disorders
CA2707047C (en) 2007-12-12 2017-11-28 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
KR20130040258A (en) * 2008-03-21 2013-04-23 노파르티스 아게 Novel heterocyclic compounds and uses therof
AU2012203026B2 (en) * 2008-03-21 2014-06-12 Novartis Ag Novel heterocyclic compounds and uses thereof
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int pharmaceutical composition comprising an inhibitor of dipeptidyl peptidase-4 (DPP4) and a companion drug
AU2009240643B2 (en) 2008-04-23 2014-03-06 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "Treatment for diabetes in patients unsuitable for therapy with metformin"
KR20190016601A (en) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
KR20110067096A (en) 2008-09-10 2011-06-21 베링거 인겔하임 인터내셔날 게엠베하 Combination therapy for the treatment of diabetes and related conditions
BRPI0923121A2 (en) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Saline forms of organic compounds
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
MX366325B (en) 2010-05-05 2019-07-05 Boehringer Ingelheim Int Combination therapy.
EA201201657A1 (en) 2010-06-24 2013-06-28 Бёрингер Ингельхайм Интернациональ Гмбх Treatment of diabetes
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2013010964A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
EP3110449A1 (en) 2014-02-28 2017-01-04 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
UY36294A (en) 2014-09-12 2016-04-29 Novartis Ag Compounds and compositions as kinase inhibitors
SG11201706347SA (en) * 2015-02-06 2017-09-28 Intercept Pharmaceuticals Inc Pharmaceutical compositions for combination therapy
EP3383389A4 (en) * 2015-11-30 2019-05-08 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as blt1 antagonists
AU2017276758A1 (en) 2016-06-10 2018-11-08 Boehringer Ingelheim International Gmbh Combinations of Linagliptin and metformin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR74148B (en) * 1980-04-03 1984-06-06 Wyeth John & Brother Ltd
IT1248528B (en) * 1991-06-21 1995-01-19 Pierrel Spa Derivatives of ethers and thioethers (hetero) aromatics having antiiperlipidemica activities, process for their preparation and pharmaceutical compositions containing them.
JP3197602B2 (en) * 1992-02-17 2001-08-13 久光製薬株式会社 Thiazole analogous compounds and skin external preparation
JPH11147881A (en) * 1997-08-21 1999-06-02 Sankyo Co Ltd Herbicidal azole derivative having dihydrobenzoquinone skeleton
AT451346T (en) * 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carboxylene derivatives and medicaments containing these as active active substances
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US20030170858A1 (en) * 2001-01-16 2003-09-11 Paul Charifson Gyrase inhibitors and uses thereof
AU7772301A (en) * 2000-08-11 2002-02-25 Nippon Chemiphar Co Ppardelta activators
US7078422B2 (en) * 2001-03-23 2006-07-18 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-activated receptor
JP2002348281A (en) * 2001-03-23 2002-12-04 Takeda Chem Ind Ltd Five-membered heterocyclic alkane acid derivative
JP4745244B2 (en) * 2003-11-05 2011-08-10 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Phenyl derivatives as PPAR agonists

Also Published As

Publication number Publication date
TW200612926A (en) 2006-05-01
EP1748993A4 (en) 2010-04-28
US20070203155A1 (en) 2007-08-30
ECSP067021A (en) 2006-12-29
BRPI0511477A (en) 2007-12-26
MA28660B1 (en) 2007-06-01
MXPA06013591A (en) 2007-03-15
JP2008500355A (en) 2008-01-10
AR049284A1 (en) 2006-07-12
WO2005116000A1 (en) 2005-12-08
RU2413723C2 (en) 2011-03-10
NO20065984L (en) 2007-02-05
EP1748993A1 (en) 2007-02-07
CA2563818A1 (en) 2005-12-08
AU2005247931A1 (en) 2005-12-08
RU2006145894A (en) 2008-06-27
PE20060315A1 (en) 2006-05-15
AU2005247931B2 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
TWI369352B (en) Compounds and compositions as hedgehog pathway modulators
IL181825D0 (en) Immunogenic composition
IL181697D0 (en) Medicinal composition
IL189856D0 (en) New formulation
GB0510139D0 (en) Novel compounds B1
IL198688D0 (en) Composition with modulating agents
GB0522477D0 (en) Modulator
PL1753831T3 (en) Coating composition
EP1746135A4 (en) Curable composition
EP1782807A4 (en) Jelly composition
SI1765327T1 (en) Compounds, compositions and methods
IL185906D0 (en) Composition
IL184421D0 (en) Fertilizer-compatible composition
EP1930012A4 (en) Cellooligosaccharide-containing composition
GB0305941D0 (en) Composition
GB0406819D0 (en) Controlled release compositions
GB0402143D0 (en) Novel compounds
GB0420888D0 (en) Compounds and uses
IN2007DE09145A (en) Compositions and methods
HK1109075A1 (en) Methods and compositions for modulating hyperstabilized c-met c-met
EP1818368A4 (en) Curable composition
IL186721D0 (en) Bioenhanced compositions
PL1948770T3 (en) Composition
GB0503337D0 (en) Compositions
EP1804803A4 (en) Compounds and compositions as hedgehog pathway modulators